Compare Repligen Corporation Common Stock (RGEN) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Victoria's Secret & Co — how do they compare? Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B), while Victoria's Secret & Co trades at $86.8 (market cap $7.08B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and Repligen Corporation Common Stock is more actively traded (1,259,263 versus 1,247,026). Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Victoria's Secret & Co for 34 Days on average.
| RGEN | VSXY | |
|---|---|---|
Market Cap | $11.14B | $7.08B |
Volume | 1,259,263 | 1,247,026 |
Sector | Health | Consumer Cyclical |
52-Week High | $194.57 | $99.97 |
52-Week Low | $102.87 | $30.19 |
Typical Hold Time | 0 Days | 34 Days |
Enterprise Value | $11.02B | $9.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Victoria's Secret (VSXY) trades at $88.39, down 0.23% today, with a bullish technical signal supported by moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and projected 2026 revenue growth to $6.9B. Recent news highlights brand momentum through fashion show expansion and omnichannel retail strategy, though valuation remains elevated at P/E 19.83 and P/B 7.16.
The outlook appears positive with 60% analyst buy ratings and projected net income growth to $378M in 2026. Key opportunities include international expansion and margin improvement, while risks involve rich valuation, rising costs, and competitive pressures in retail apparel. The stock trades near consensus target of $86.80 with upside potential to $101.00.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
